Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.11 USD | +3.17% | +1.20% | +123.85% |
Jun. 02 | Transcript : Cullinan Therapeutics, Inc. - Special Call | |
Jun. 01 | Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+123.85% | 1.29B | |
+48.15% | 57.87B | |
+41.65% | 40.25B | |
-6.85% | 39.94B | |
-5.96% | 28.54B | |
+12.98% | 26.4B | |
-20.42% | 19.33B | |
+31.30% | 12.4B | |
-0.13% | 12.23B | |
+24.74% | 12.2B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Oncology Secures FDA Approval for CLN-619's Investigational New Drug Application in Multiple Myeloma